Health Insurance Expansion Likely to Increase HTN Treatment

Share this content:
Health Insurance Expansion Likely to Increase HTN Treatment
Health Insurance Expansion Likely to Increase HTN Treatment

(HealthDay News) -- Efforts to expand health insurance coverage are expected to lead to increased treatment rates among nonelderly patients with hypertension, which will have significant health benefits, according to a study published online July 2 in the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.

Suhui Li, Ph.D., from The George Washington University in Washington D.C., and colleagues developed a state-transition model to simulate lifetime health events of the population aged 25 to 64 years. The effects of insurance coverage expansions were modeled on the basis of published findings on the correlation between insurance coverage, use of antihypertensive medications, and cardiovascular disease (CVD)-related events and deaths.

The researchers found that among patients with hypertension, currently anticipated health insurance expansions would lead to a 5.1 percent increase in treatment rates. By 2050, this increase would be expected to lead to 111,000 fewer new coronary heart disease events, 63,000 fewer stroke events, and 95,000 fewer CVD-related deaths. Slightly greater estimated benefits were seen for men than women, and for nonwhite populations.

"Federal and state efforts to expand insurance coverage among nonelderly adults could yield significant health benefits in terms of CVD prevalence and mortality rates and narrow the racial/ethnic disparities in health outcomes for patients with hypertension," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FDA Panel Has Tie Vote on New Type ...

Zynquista is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years

Frailty Could Increase Susceptibility for Dementia

Frailty Could Increase Susceptibility for Dementia

Authors say frailty should be considered in clinical care, management of Alzheimer dementia

is free, fast, and customized just for you!




Already a member?

Sign In Now »